Acta Scientific Microbiology (ISSN: 2581-3226)

Editorial Volume 5 Issue 6

COVID-19 Severity with Omicron Variant Infection

Attapon Cheepsattayakorn1,3*, Ruangrong Cheepsattayakorn2 and Porntep Siriwanarangsun3

110th Zonal Tuberculosis and Chest Disease Center, Chiang Mai, Thailand
2Department of Pathology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
3Faculty of Medicine, Western University, Pathumtani Province, Thailand

*Corresponding Author: Attapon Cheepsattayakorn, 10th Zonal Tuberculosis and Chest Disease Center, Chiang Mai, Thailand.

Received: April 25, 2022; Published: April 29, 2022


A recent study in South Africa demonstrated that IgG seroprevalence of SARS-CoV-2 (COVID-19) ranged from 56.2% (95% confidential interval (CI), 52.6 to 59.7) among children with age younger than 12 years to 79.7% (95% CI, 77.6 to 81.5) among adults with age older than 50 years [1]. Female patients were higher IgG-seroprevalence levels than male cases [1]. The Omicron variant was predominant during the latest COVID-19-pandemic fourth wave in this country with one month from the onset to the peak of this latest wave, compared to the previous third wave of the COVID-19 pandemic, whereas the incidences of hospital admission, excess death attributable to COVID-19 in this latest fourth wave were consistently lower than the earlier waves’ incidences [1]. In Omicron variant that mainly affecting spike protein, cell-mediated immunity is likely to be more durable than neutralizing-antibody-mediated immunity in the small mutation context [2], whereas natural infection induces cell-mediated immunity targeting membrane protein, nucleocapsid protein, and spike protein [3] and long-lived cytotoxic (CD8+) T cells with a half-life of 125 to 255 days [4].


  1. Madhi SA., et al. “Population Immunity and Covid-19 Severity with Omicron Variant in South Africa”. The New England Journal of Medicine 386 (2022): 1314-1326.
  2. Alter G., et al. “Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans”. Nature 596 (2021): 268-272.
  3. Milne G., et al. “Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity ?” Lancet Respiratory Medicine 9 (2021): 1450-1466.
  4. Dan IM., et al. “Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection”. Science 371 (2021): eabf45063.


Citation: Attapon Cheepsattayakorn., et al. “COVID-19 Severity with Omicron Variant Infection". Acta Scientific Microbiology 5.5 (2022): 01.


Copyright: © 2022 Attapon Cheepsattayakorn., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Acceptance rate30%
Acceptance to publication20-30 days

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is July 10, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US